AI in Life Science Market
AI in Life Science Market by Offering (End-to-End, Niche/Point, AI Tech), Application (Drug Discovery, Clinical Trials, Quality Assurance, Regulatory), Tool (Machine Learning, NLP, Computer Vision), End User (Pharma, Biotech) - Global Forecast to 2031
AI IN LIFE SCIENCE MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global AI in life science market is projected to grow from USD 21.58 billion in 2026 to USD 69.34 billion by 2031, at a CAGR of 26.3% during the forecast period. The market was valued at USD 17.08 billion in 2025. This rapid growth is largely driven by the maturation of AI into clinically validated products. Evidence of this trend is evident in the rapid number of approvals and deployments of AI-based solutions within healthcare organizations. According to data published by the US FDA, more than 1,450 AI/ML-enabled medical devices had been authorized by 2025. In 2025 alone, nearly 300 approvals were granted, signaling faster commercialization of AI products. Similarly, new developments suggest increasing institutional acceptance of AI. In May 2025, the FDA announced agency-wide deployment of generative AI tools to accelerate scientific review processes, reducing tasks that previously took days to minutes. This growing regulatory acceptance and operational integration of AI are reinforcing market expansion across the life sciences ecosystem.
KEY TAKEAWAYS
-
By RegionNorth America accounted for the largest share of 48.9% of the AI in life science market in 2025.
-
By Offering TypeIn 2025, the end-to-end solutions segment accounted for the largest share (37.5%) of the AI in life science market.
-
By ApplicationThe clinical applications segment accounted for the largest share of the AI in life science market in 2025.
-
By ComponentThe software segment is projected to register the highest growth rate in the AI in life science market.
-
By End UserThe pharmaceutical companies segment accounted for the largest share (37.5%) of the AI in life science market in 2025.
-
Competitive Landscape - Key PlayersNVIDIA Corporation, Illumina, Inc., and Tempus AI, Inc. were identified as some of the star players in the AI in life science market, given their strong market share and product footprint.
-
Competitive Landscape - Startups/SMEsSynthio Labs Ltd, Bioptimus, and Karyon Bio have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
Factors shaping the AI in life sciences market include the growing adoption of real-world data in clinical research, the increasing use of AI/GenAI in drug discovery and diagnostics, and the shift toward patient-centric and precision medicine models. However, challenges such as the lack of standardized validation frameworks for AI models, evolving regulatory guidelines, and concerns about data privacy, interoperability, and model reliability continue to affect the market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Al in the life sciences market is undergoing a major shift, with a growing focus on continuous, real-world data generation and passive monitoring through Al-enabled platforms. The widespread use of connected devices, electronic health records, and digital health tools is enabling continuous data capture, allowing Al models to generate deeper, more dynamic insights across the patient journey. Moreover, there is an increasing emphasis on cognitive and behavioral Al analytics, covering speech recognition, patient behavior, activity levels, and interactions. Such an approach opens up new possibilities for disease prediction, patient stratification, and long-term health monitoring. In turn, there is a shift toward the use of Al solutions in real-world applications. Namely, Al can now be used to monitor and manage conditions that do not necessarily require a visit to the doctor's office.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Acceleration of drug discovery
-
Increasing demand for personalized medicine
Level
-
High cost of implementation of life science solutions
-
Regulatory and ethical concerns
Level
-
Expanding personalized medicine
-
Growing adoption of AI-driven drug discovery
Level
-
Data quality and integration challenges
-
Shortage of skilled AI and healthcare talent
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Acceleration of Drug Discovery
The transformative impact of artificial intelligence on drug discovery and development is a major driver of adoption in the life sciences industry. The traditional approach to drug discovery is typically time-consuming and costly, taking more than a decade and costing hundreds of billions of dollars. AI addresses these issues by quickly and accurately identifying targets, designing molecules, and predicting drug efficacy. AI algorithms are increasingly used by pharmaceutical companies to analyze large, complex datasets, such as genomics and proteomics, to identify ideal candidates for optimization in preclinical studies. Time-to-market decreases significantly, increasing the likelihood of success in clinical trials that start early enough to identify the risks involved. With the potential to substantially decrease costs and improve outcomes, AI-driven drug discovery is emerging as a key driver of innovation in the life sciences sector, attracting significant investment and accelerating market growth.
Restraint: High Cost of Implementation of Life Science Solutions
The very high implementation cost of AI technology is a significant barrier to adoption in the life sciences market. Integrating these technologies with existing infrastructure requires upfront investment in hardware, software, and personnel. High upfront costs can substantially burden small life sciences firms or those in resource-scarce regions. The cost of acquiring and, more importantly, maintaining sophisticated AI technologies, along with the need to continually update the system or train personnel, also adds significantly to the bills. Most organizations face difficult decisions when immediate returns from such investments are limited. Therefore, though AI holds enormous promise to increase efficiency, speed drug discovery, and revolutionize patient care, its implementation cost remains a major challenge. These costs may be too high, delaying the wide-scale introduction of AI into life sciences, especially when budgets are tight and the decision to invest in AI for an extended period seems too high-risk.
Opportunity: Expanding Personalized Medicine
One of the key drivers of AI growth in the life sciences market is the increasing use of personalized medicine. As patient data, including genetic, clinical, and lifestyle information, grows, it is increasingly analyzed with AI technologies to develop tailor-made treatments and therapies. From this information, AI can aid in pattern recognition and correlation analysis, forming a basis for developing more efficient, targeted healthcare solutions that suit each patient's specific needs. These targeted approaches lead to better patient outcomes while also making treatment procedures more efficient by reducing the trial-and-error processes that come with most forms of conventional medicine. Additionally, this will contribute to the development of new biomarkers and therapeutic targets, advancing the cause of precision medicine. There is a growing demand for more personalized healthcare solutions, and AI's role in drug development, diagnostics, and treatment planning represents a significant opportunity for innovation and growth in the life sciences industry. This shift toward personalized medicine is expected to transform healthcare delivery by making it more effective, cost-effective, and patient-centered, accelerating the adoption of AI technologies across the life sciences industry.
Challenge: Data Quality and Integration Challenges in Al for Life Sciences
Data quality and integration pose the greatest challenges to AI adoption in the life sciences market. AI algorithms require large amounts of data to generate precise and meaningful insights, yet data used in life sciences are often inconsistent and fragmented. This means that siloed electronic health records, clinical trials, genomics, and wearable devices in incompatible formats make it difficult for AI to aggregate and standardize them. Health data might also be noisy, incomplete, or biased, which could result in incorrect predictions and decisions by AI. Poor-quality data can undermine effective solutions offered by AI, especially in sensitive areas such as drug development, diagnostics, and patient treatment planning. As AI is embraced in life sciences, there is an imperative need to ensure that abundant data is clean, standardized, and interoperable across all platforms and systems. Without addressing these data-related challenges, the full potential of AI in the life sciences market will remain constrained, limiting the achievement of reliable, actionable insights and further limiting the broader impact of AI in healthcare innovation.
AI IN LIFE SCIENCE MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
AI-enabled genomics platforms for sequencing data analysis, variant interpretation, and biomarker discovery | Faster genomic insights, improved precision medicine, and enhanced disease risk prediction |
 |
AI platform integrating clinical and molecular data for oncology decision support and real-world evidence generation | Personalized treatment recommendations, improved clinical outcomes, and better research insights |
 |
AI-driven phenomics platform combining imaging and machine learning for high-throughput drug discover | Accelerated target identification, scalable experimentation, and reduced drug discovery timelines |
 |
AI-powered simulation platform (3DEXPERIENCE) for virtual human modeling and in-silico drug/device testing | Reduced R&D costs, faster regulatory submissions, and minimized reliance on animal testing |
 |
Physics-based and AI-driven computational platform for molecular modeling and drug design | Improved molecule optimization, higher success rates in lead discovery, and faster pipeline progression |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The ecosystem for AI in the life sciences market comprises several stakeholder groups spanning technologies, research, and healthcare. These include providers of advanced computing technology, AI frameworks, and cloud solutions, such as NVIDIA Corporation, Microsoft Corporation, and Google Cloud. AI-based life sciences companies also specialize in developing AI-driven drug discovery or molecular modeling platforms, such as Insilico Medicine Ltd., Recursion Pharmaceuticals, Inc., and Schrodinger, Inc. Data generation and integration enablers include genomics companies, clinical data platforms, and real-world evidence providers that supply the structured or unstructured data required to train AI models. The ecosystem is completed by cloud and data infrastructure providers, such as Amazon Web Services and Google Cloud, which facilitate large-scale implementation of AI solutions. End users of these services include pharmaceutical and biotech companies, as well as contract research organizations (CROs). Key participants in the ecosystem include regulatory organizations, such as the US FDA and EMA.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
AI in Life Science Market, By Offering
The end-to-end solution subsegment has the highest market share in the AI in life sciences industry due to the rising need for platform integration, which helps simplify processes related to drug discovery, clinical research, and commercialization. End-to-end solutions support data integration, model deployment, and collaboration across departments, minimizing the complexities associated with these processes. Organizations prefer to adopt an end-to-end solution over several individual solutions due to the scalability and efficiency provided by the former approach.
AI in Life Science Market, By Application
It is anticipated that the clinical application segment will experience rapid growth, driven by the increased use of AI in diagnosis, clinical trial enhancement, and patient management. Artificial intelligence is revolutionizing patient acquisition, monitoring, and outcome forecasting, making clinical trials more effective and successful. Furthermore, the transition toward personalized medicine and clinical decision-making is fueling adoption. Moreover, the growing incorporation of artificial intelligence in imaging, disease detection, and overall clinical processes is boosting its role in the healthcare sector.
AI in Life Science Market, By Component
The software sector holds the largest market share because AI-based software applications serve as the backbone for data analytics, model building, and implementation in the life sciences. These applications enable complex analytics and automated modeling across various processes in research and clinical settings. The demand for scalable, interoperable, and easy-to-use AI software continues to grow as businesses seek to adopt AI technology in their enterprise operations. Moreover, software applications help ensure compliance with data regulations and standards, making them integral to both clinical and non-clinical segments.
AI in Life Science Market, By Tool
The natural language processing (NLP) market will experience the fastest growth due to the growing demand for analyzing unstructured data such as clinical notes, research papers, and regulatory guidelines. The use of natural language processing technology enables efficient data processing, which will support effective decision-making during research and clinical processes. With the advent of advanced language processing models, capabilities have improved in domains such as literature mining, clinical documentation, and pharmacovigilance.
AI in Life Science Market, By Deployment Mode
Cloud-based services have the largest market share, driven by their scalability, flexibility, and affordability when handling large and complex data sets. With cloud-based systems, there are no issues with remote collaboration, deploying AI models, or integrating multiple data sources. Cloud-based solutions also support HPC requirements necessary for AI workloads such as genomics and drug discovery. Companies now adopt a “cloud-first approach” to be more flexible and reduce infrastructure costs.
AI in Life Science Market, By End User
It is predicted that the biotechnology sector will grow faster due to its innovative orientation and early adoption of new technologies. Biotechnology companies are utilizing AI to carry out tasks such as target identification and molecular modeling, as well as to advance precision medicine. Given the nature of the work carried out by biotechnology companies, it is easier to incorporate AI rapidly into their operations. The increased flow of investments and collaboration with technology companies in this sector is also helping increase the use of AI.
REGION
Asia Pacific to register highest CAGR in AI in life science market during forecast period
The market for AI in the life sciences industry in the Asia Pacific region is showing rapid growth on account of the adoption of AI-enabled healthcare systems in the region. The region is witnessing a shift towards an AI-enabled healthcare system, where countries are now moving toward the implementation of AI in their healthcare system beyond piloting initiatives. One such driving factor is the increasing adoption rate within healthcare organizations. As per IDC (2026), approximately 75% of healthcare organizations in Asia Pacific anticipate increased productivity because of AI-powered systems, pointing to increased institutional adoption of AI. Moreover, as per the Philips Future Health Index 2025, 89% of healthcare professionals in Asia Pacific consider that AI could save lives due to its early intervention ability.
AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX
Illumina, Inc. (Star Player) is a key player in the AI in life sciences market, leveraging its leadership in genomics and AI-driven data analytics. Its platforms enable large-scale genomic analysis for precision medicine, biomarker discovery, and drug development, setting a benchmark for data-driven innovation. Dassault Systèmes (Emerging Leader) is expanding in the market through AI-powered simulation and its 3DEXPERIENCE platform for virtual human modeling and in-silico development. While Illumina leads with strong genomics capabilities, it faces growing competition from players like Dassault Systèmes advancing AI-based simulation in life sciences.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- NVIDIA Corporation (US)
- Illumina, Inc. (US)
- Tempus AI, Inc. (US)
- Recursion Pharmaceuticals, Inc. (US)
- Dassault Systèmes SE (France)
- Schrödinger, Inc. (US)
- Data4Cure, Inc. (US)
- Microsoft Corporation (US)
- Insilico Medicine Ltd. (Hong Kong)
- BenevolentAI Limited (UK)
- Owkin, Inc. (France)
- PathAI, Inc. (US)
- Aidoc Medical Ltd. (Israel)
- Qure.ai Technologies Pvt. Ltd. (India)
- Deep Genomics Inc. (Canada)
- SOPHiA GENETICS SA (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 | USD 17.08 Billion |
| Market Size in 2026 | USD 21.58 Billion |
| Market Forecast in 2031 | USD 69.34 Billion |
| CAGR | 26.3% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | USD Billion |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Middle East & Africa, Latin America |
WHAT IS IN IT FOR YOU: AI IN LIFE SCIENCE MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Mapping | In-depth analysis of key AI in life sciences companies, their platforms, solutions, and market positioning across drug discovery, clinical development, diagnostics, and real-world data analytics, along with evaluation of AI technologies such as ML, NLP, and computer vision | Enables benchmarking of AI capabilities, identifies differentiation opportunities across platforms and technologies, and supports strategic partnerships, licensing, and M&A decision-making |
| Market Entry & Growth Strategy | Regional and segment-level assessment of the AI in life sciences market, including adoption trends, healthcare infrastructure maturity, investment landscape, and regulatory acceptance across pharmaceutical, biotech, and healthcare sectors | Reduces go-to-market risk, accelerates adoption through localized strategies, and supports expansion into high-growth regions and emerging AI-driven healthcare ecosystems |
| Regulatory & Operational Risk Analysis | Evaluation of compliance requirements for AI in life sciences, including FDA, EMA, HIPAA, GDPR, and emerging AI-specific regulations, along with considerations for data governance, model validation, explainability, and ethical AI use in clinical and research settings | Supports regulatory readiness, mitigates operational and compliance risks, and enhances credibility in AI-driven clinical and research applications while ensuring alignment with patient safety and data privacy standards |
| Technology Adoption Trends | Insights into the adoption of AI technologies across life sciences, including AI-driven drug discovery, clinical trial optimization, diagnostics, real-world evidence generation, and integration of multi-omics and clinical datasets with advanced analytics | Guides R&D prioritization, informs investment in AI platforms and infrastructure, and helps organizations align AI strategies with improved clinical outcomes, operational efficiency, and data-driven decision-making |
RECENT DEVELOPMENTS
- June 2024 : Medidata, a Dassault Systèmes brand, launched Medidata Clinical Data Studio, a unified platform enhancing clinical research data management. This innovation empowered stakeholders to improve data quality and accelerate safer trials for patients.
- April 2024 : IQVIA and Salesforce, the leading Al-powered CRM, announced an expanded partnership to advance Salesforce's Life Sciences Cloud, a next-generation customer engagement platform for the life sciences sector.
- March 2024 : Clarivate Plc announced an agreement to acquire most assets of MotionHall, a Silicon Valley startup specializing in AI solutions for life sciences. This move aligns with Clarivate's strategy to enhance its Life Sciences & Healthcare offerings through generative AI and proprietary industry-focused solutions.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.
AI in Life Science Market : Top-Down and Bottom-Up Approach
Data Triangulation
After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market.
Market Definition
AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.
Key Stakeholders
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs) & Clinical Trial Partners
- Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
- Digital Health & AI Solution Providers
- Cloud & Data Infrastructure Providers
- Data Analytics & Software Platform Providers
- Payers & Insurance Companies
- Regulatory & Compliance Bodies (e.g., FDA, EMA)
- Academic & Research Institutions
- Patients & End Users
- Technology Integrators & Consulting Firms
Report Objectives
- To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company.
Regional Analysis
- Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the AI in Life Science Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in AI in Life Science Market